MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritis
13. November 2024 08:00 ET
|
MoonLake Immunotherapeutics AG
MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritis Two trials for active psoriatic arthritis (PsA) with one focusing on...
MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update
07. November 2024 07:00 ET
|
MoonLake Immunotherapeutics AG
MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update Ended the third quarter with $493.9 million in cash, cash equivalents and short-term marketable...
MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11
09. September 2024 07:00 ET
|
MoonLake Immunotherapeutics AG
MoonLake Immunotherapeutics to host a Capital Markets Updateon Wednesday, September 11ZUG, Switzerland, September 9, 2024 – MoonLake Immunotherapeutics AG (“MoonLake”; Nasdaq: MLTX), a clinical-stage...
MoonLake Immunotherapeutics Reports Second Quarter 2024 Financial Results and Announces a Capital Markets Update for September 11
07. August 2024 08:00 ET
|
MoonLake Immunotherapeutics AG
MoonLake Immunotherapeutics Reports Second Quarter 2024 Financial Results and Announces a Capital Markets Update for September 11 Initiated Phase 3 VELA program of the Nanobody® sonelokimab in...
MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase 3 Program for the Nanobody® sonelokimab in Psoriatic Arthritis
10. Juni 2024 08:00 ET
|
MoonLake Immunotherapeutics AG
MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase 3 Program for the Nanobody® sonelokimab in Psoriatic Arthritis Builds upon the positive...
MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa
16. Mai 2024 08:00 ET
|
MoonLake Immunotherapeutics AG
MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa VELA is the first Phase 3 program in hidradenitis...
MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update
07. Mai 2024 08:00 ET
|
MoonLake Immunotherapeutics AG
MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update Announced positive feedback from both FDA and EMA on the regulatory path for the Phase 3...
MoonLake Immunotherapeutics inks three-year technology partnership with Komodo Health to advance research on inflammatory skin and joint conditions
10. April 2024 07:00 ET
|
MoonLake Immunotherapeutics AG
MoonLake Immunotherapeutics inks three-year technology partnership with Komodo Health to advance research on inflammatory skin and joint conditions MoonLake to tap into Komodo’s technology and...
MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day
10. März 2024 12:00 ET
|
MoonLake Immunotherapeutics AG
MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day Positive 24-week data from...
MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024
04. März 2024 08:00 ET
|
MoonLake Immunotherapeutics AG
MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024 ZUG, Switzerland, March 4, 2024 – MoonLake...